Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Doctors.net.uk

Lucid strengthens its creative services department

There’s no slowing down for Lucid Group as it completes its first decade of trading early next year. In parallel with the recent appointments in its senior leadership team, Lucid...

Lucid Group Communications Limited

Bristol-Myers Squibb (BMS) building

NICE backs BMS leukaemia drug Sprycel

Watchdog approves blood cancer therapy for use by NHS in England and Wales

Roche's Perjeta pertuzumab

NICE backs Roche’s Perjeta for routine NHS use

Set to become first new breast cancer drug in nine years after discount agreed

- PMLiVE

The rise and rise of Generation Now

Investigating the positive changes millennials are bringing to healthcare

- PMLiVE

Changing behaviour: putting theory into practice

In the November issue of PME, Madeleine Tye (senior account manager at Lucid Group) discusses Lucid’s approach to medical education. Lucid employs the outcomes of research into behavioural science in...

Lucid Group Communications Limited

Tajinder’s #LucidLife

Medical writers are like gold dust, so when we find talented writers with great experience,we offer a tailor-made package.Are you a world-class medical writer?Do you like the look of Tajinder’s...

Lucid Group Communications Limited

Fiona’s #LucidLife

Meet Fiona, a medical writer.She told us what she wanted, and we did the rest.We believe that medical writers are like gold dust; so when we find talent, we do...

Lucid Group Communications Limited

- PMLiVE

NICE backs expanded use of Brilique in final guidance

AZ’s maintenance therapy recommended for long-term use, post-heart attack

- PMLiVE

NICE backs Eisai’s Halaven for breast cancer

Reverses 2012 rejection due to new data and patient access discount

- PMLiVE

NICE set to reject Merck’s Erbitux for head and neck cancer

Draft guidance rules the treatment does not provide value for money

Communicating with payers to improve patient access

A transforming NHS brings with it many opportunities. Working with payers to put patients at the heart of everything while reducing costs is fundamental to success.

- PMLiVE

UK to cut wait to innovative treatments by four years

Proposals in the Accelerated Access Review aim to speed up access to innovation

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links